Cns Pharmaceuticals Inc (CNSP)

$5.42 +0.37 (7.33%)
Market Cap 4.14M
Revenue (ttm) 0.00
Net Income (ttm) -15.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 23,800
Avg Vol 1,759,956
Day's Range N/A - N/A
Shares Out 811,000.00
Stochastic %K 15%
Beta 2.62
Analysts Strong Sell
Price Target $10.00

Company Profile

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.

Industry: Biotechnology
Sector: Healthcare
Phone: 800 946 9185
Address:
2100 West Loop South, Suite 900, Houston, United States
ClarityOfPurpose2
ClarityOfPurpose2 May. 22 at 7:57 PM
$CNSP The progress made so far is that they didn’t go bankrupt or get delisted. They have enough money now to keep the lights on and pay the executive salaries and to think big thoughts for a while longer. Until the next reverse split and private placement.
0 · Reply
NetworkNewsWire
NetworkNewsWire May. 22 at 7:15 PM
Study Finds That Errors in Brain Cell Division Could Trigger Cancer $CNSP https://ibn.fm/uJ1L4 #biomed #stocks
0 · Reply
Sw1ngb0t
Sw1ngb0t May. 22 at 12:51 AM
$CNSP $VRAX weekly gap always fills... one of my new things. I really like these though
0 · Reply
30PERCENT40
30PERCENT40 May. 21 at 10:48 PM
$CNSP
0 · Reply
Sw1ngb0t
Sw1ngb0t May. 20 at 5:52 PM
$CNSP $2.40 then $40... you heard it here first
1 · Reply
Sw1ngb0t
Sw1ngb0t May. 20 at 2:51 PM
$CNSP let it come down to $2.40 then fill the boots
0 · Reply
VirtualInvestor
VirtualInvestor May. 20 at 1:49 PM
$CNSP CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company’s Recent Strategic Transformation Progress https://vimeo.com/1193965352/6cf0543a22
0 · Reply
focafoca99
focafoca99 May. 20 at 1:11 PM
$CNSP outlined its recent $22.5 million financing and strategic transformation progress during a virtual CEO Connect segment.
0 · Reply
Sw1ngb0t
Sw1ngb0t May. 20 at 12:13 PM
$CNSP I say $4 will be a good entry... let's see
0 · Reply
Sw1ngb0t
Sw1ngb0t May. 20 at 2:17 AM
$WOK (gotta watch this one...) $CNSP $CMND $ONFO $CMND
1 · Reply
Latest News on CNSP
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress

May 20, 2026, 9:02 AM EDT - 2 days ago

CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress

CNS Pharmaceuticals files to sell 9.79M shares of common stock for holders

2026-05-19T21:01:10.000Z - 3 days ago

CNS Pharmaceuticals files to sell 9.79M shares of common stock for holders

CNS Pharmaceuticals Registration statement: Registration filing

May 19, 2026, 8:00 AM EDT - 3 days ago

CNS Pharmaceuticals Registration statement: Registration filing

CNS Pharmaceuticals reports Q1 EPS ($7.30) vs. ($18.93) last year

2026-05-14T16:25:17.000Z - 8 days ago

CNS Pharmaceuticals reports Q1 EPS ($7.30) vs. ($18.93) last year

CNS Pharmaceuticals sees cash runway ‘beyond’ twelve months

2026-05-14T16:22:47.000Z - 8 days ago

CNS Pharmaceuticals sees cash runway ‘beyond’ twelve months

CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress

May 14, 2026, 8:00 AM EDT - 8 days ago

CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress

CNS Pharmaceuticals Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 8 days ago

CNS Pharmaceuticals Quarterly report: Q1 2026

CNS Pharmaceuticals Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 8 days ago

CNS Pharmaceuticals Earnings release: Q1 2026

3 Penny Stocks to Watch Now, 5/5/26

2026-05-05T16:22:32.000Z - 17 days ago

3 Penny Stocks to Watch Now, 5/5/26

ELPW PN

Why Is CNS Pharmaceuticals Stock (CNSP) Up Today?

2026-05-04T13:58:45.000Z - 18 days ago

Why Is CNS Pharmaceuticals Stock (CNSP) Up Today?

CNS Pharmaceuticals prices 650,000 shares at $2.30 in private placement

2026-05-04T11:19:29.000Z - 18 days ago

CNS Pharmaceuticals prices 650,000 shares at $2.30 in private placement

CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing

May 4, 2026, 7:00 AM EDT - 18 days ago

CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing

CNS Pharmaceuticals Slides: Investor presentation

Apr 22, 2026, 7:00 AM EDT - 4 weeks ago

CNS Pharmaceuticals Slides: Investor presentation

CNS Pharmaceuticals Annual report: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 7 weeks ago

CNS Pharmaceuticals Annual report: Q4 2025

CNS Pharmaceuticals launches new corporate growth strategy

2026-03-11T12:52:04.000Z - 2 months ago

CNS Pharmaceuticals launches new corporate growth strategy

CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline

Mar 11, 2026, 8:35 AM EDT - 2 months ago

CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline

CNS Pharmaceuticals appoints Lynne Kelley as CMO

2026-03-02T13:42:54.000Z - 2 months ago

CNS Pharmaceuticals appoints Lynne Kelley as CMO

CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team

Mar 2, 2026, 8:25 AM EST - 2 months ago

CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team

CNS Pharmaceuticals appoints Steven O’Loughlin as CFO, Dylan Wenke as CBO

2026-02-17T13:45:41.000Z - 3 months ago

CNS Pharmaceuticals appoints Steven O’Loughlin as CFO, Dylan Wenke as CBO

CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation

Feb 17, 2026, 8:25 AM EST - 3 months ago

CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation

CNS Pharmaceuticals says priority ‘is to transform’ how company operates

2026-01-27T14:15:45.000Z - 4 months ago

CNS Pharmaceuticals says priority ‘is to transform’ how company operates

CNS Pharmaceuticals Issues Letter to Shareholders

Jan 27, 2026, 9:00 AM EST - 4 months ago

CNS Pharmaceuticals Issues Letter to Shareholders

CNS Pharmaceuticals Inc trading resumes

2026-01-15T14:45:16.000Z - 4 months ago

CNS Pharmaceuticals Inc trading resumes

CNS Pharmaceuticals Inc trading halted, volatility trading pause

2026-01-15T14:35:44.000Z - 4 months ago

CNS Pharmaceuticals Inc trading halted, volatility trading pause

CNS Pharmaceuticals CEO John Climaco steps down, Rami Levin succeeds

2025-12-17T12:15:58.000Z - 5 months ago

CNS Pharmaceuticals CEO John Climaco steps down, Rami Levin succeeds

CNS Pharmaceuticals Announces CEO Transition

Dec 17, 2025, 7:00 AM EST - 5 months ago

CNS Pharmaceuticals Announces CEO Transition

CNS Pharmaceuticals reports Q3 EPS ($5.76) vs. ($153.20) last year

2025-11-17T14:01:48.000Z - 6 months ago

CNS Pharmaceuticals reports Q3 EPS ($5.76) vs. ($153.20) last year

CNS Pharmaceuticals sees cash runway into 2H26

2025-11-17T14:01:42.000Z - 6 months ago

CNS Pharmaceuticals sees cash runway into 2H26

CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 17, 2025, 8:35 AM EST - 6 months ago

CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 6 months ago

CNS Pharmaceuticals Quarterly report: Q3 2025

CNS Pharmaceuticals Proxy statement: Proxy Filing

Nov 12, 2025, 7:00 AM EST - 6 months ago

CNS Pharmaceuticals Proxy statement: Proxy Filing

CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting

Nov 10, 2025, 8:45 AM EST - 6 months ago

CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting

CNS Pharmaceuticals Proxy statement: Proxy Filing

Oct 24, 2025, 8:00 AM EDT - 7 months ago

CNS Pharmaceuticals Proxy statement: Proxy Filing

CNS Pharmaceuticals Proxy statement: Proxy Filing

Oct 10, 2025, 8:00 AM EDT - 8 months ago

CNS Pharmaceuticals Proxy statement: Proxy Filing

CNS Pharmaceuticals upgraded to Buy at Maxim on TPI-287 roadmap

2025-09-12T13:05:32.000Z - 9 months ago

CNS Pharmaceuticals upgraded to Buy at Maxim on TPI-287 roadmap

CNS Pharmaceuticals upgraded to Buy from Hold at Maxim

2025-09-12T11:50:09.000Z - 9 months ago

CNS Pharmaceuticals upgraded to Buy from Hold at Maxim

CNS Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:00 AM EDT - 9 months ago

CNS Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:15 AM EDT - 9 months ago

CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

CNS Pharmaceuticals reports Q2 EPS ($6.42) vs. ($4,049.20) last year

2025-08-15T12:10:39.000Z - 10 months ago

CNS Pharmaceuticals reports Q2 EPS ($6.42) vs. ($4,049.20) last year

CNS Pharmaceuticals sees cash runway into 2H26

2025-08-15T12:10:34.000Z - 10 months ago

CNS Pharmaceuticals sees cash runway into 2H26

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 15, 2025, 8:05 AM EDT - 10 months ago

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 10 months ago

CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

CNS Pharmaceuticals Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 10 months ago

CNS Pharmaceuticals Earnings release: Q2 2025

CNS Pharmaceuticals Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 10 months ago

CNS Pharmaceuticals Quarterly report: Q2 2025

CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 10 months ago

CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

CNS Pharmaceuticals Announces Reverse Stock Split

Jul 18, 2025, 8:00 AM EDT - 11 months ago

CNS Pharmaceuticals Announces Reverse Stock Split

CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment

Jul 9, 2025, 9:32 AM EDT - 11 months ago

CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

Jun 24, 2025, 9:15 AM EDT - 11 months ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

Jun 5, 2025, 8:05 AM EDT - 1 year ago

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 16, 2025, 8:05 AM EDT - 1 year ago

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals Quarterly report: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

CNS Pharmaceuticals Quarterly report: Q1 2025

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

May 13, 2025, 9:35 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

May 13, 2025, 7:00 AM EDT - 1 year ago

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

CNS Pharmaceuticals Registration statement: Registration Filing

May 12, 2025, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Registration statement: Registration Filing

CNS Pharmaceuticals Registration statement: Registration Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Registration statement: Registration Filing

CNS Pharmaceuticals Earnings release: Q4 2024

Apr 1, 2025, 4:00 PM EDT - 1 year ago

CNS Pharmaceuticals Earnings release: Q4 2024

CNS Pharmaceuticals Annual report: Q4 2024

Apr 1, 2025, 4:00 PM EDT - 1 year ago

CNS Pharmaceuticals Annual report: Q4 2024

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

Apr 1, 2025, 8:05 AM EDT - 1 year ago

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

Mar 25, 2025, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

Feb 26, 2025, 9:05 AM EST - 1 year ago

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

Feb 20, 2025, 9:00 AM EST - 1 year ago

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

Feb 18, 2025, 9:00 AM EST - 1 year ago

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

Feb 10, 2025, 8:00 AM EST - 1 year ago

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

CNS Pharmaceuticals Transcript: Investor Update

Dec 11, 2024, 11:30 AM EST - 1 year ago

CNS Pharmaceuticals Transcript: Investor Update

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

Dec 5, 2024, 9:10 AM EST - 1 year ago

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

Nov 25, 2024, 9:00 AM EST - 1 year ago

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

Nov 18, 2024, 8:55 AM EST - 1 year ago

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 15, 2024, 9:10 AM EST - 1 year ago

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

CNS Pharmaceuticals Proxy statement: Proxy Filing

Nov 15, 2024, 7:00 AM EST - 1 year ago

CNS Pharmaceuticals Proxy statement: Proxy Filing

CNS Pharmaceuticals Quarterly report: Q3 2024

Nov 14, 2024, 4:00 PM EST - 1 year ago

CNS Pharmaceuticals Quarterly report: Q3 2024

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

Nov 4, 2024, 9:15 AM EST - 1 year ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Nov 1, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals Proxy statement: Proxy Filing

Oct 28, 2024, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Proxy statement: Proxy Filing

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 23, 2024, 2:50 PM EDT - 1 year ago

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

CNS Pharmaceuticals Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 16, 2024, 4:00 PM EDT - 1 year ago

CNS Pharmaceuticals Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

CNS Pharmaceuticals Proxy statement: Proxy Filing

Oct 15, 2024, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Proxy statement: Proxy Filing

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

Oct 10, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

Oct 8, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

Sep 23, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

Sep 12, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

CNS Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

Sep 3, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Aug 27, 2024, 9:10 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

CNS Pharmaceuticals Transcript: Virtual Investor CEO Connect

Aug 26, 2024, 12:00 PM EDT - 1 year ago

CNS Pharmaceuticals Transcript: Virtual Investor CEO Connect

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

Aug 22, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 15, 2024, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

CNS Pharmaceuticals Quarterly report: Q2 2024

Aug 13, 2024, 6:00 PM EDT - 1 year ago

CNS Pharmaceuticals Quarterly report: Q2 2024

CNS Pharmaceuticals Transcript: Investor Update

Jul 30, 2024, 8:30 AM EDT - 1 year ago

CNS Pharmaceuticals Transcript: Investor Update

CNS Pharmaceuticals Press release: Investor Update

Jul 30, 2024, 8:30 AM EDT - 1 year ago

CNS Pharmaceuticals Press release: Investor Update

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

Jul 30, 2024, 7:00 AM EDT - 1 year ago

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

Jul 25, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

CNS Pharmaceuticals Registration statement: Registration Filing

Jul 19, 2024, 8:00 AM EDT - 2 years ago

CNS Pharmaceuticals Registration statement: Registration Filing

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

Jul 16, 2024, 9:15 AM EDT - 2 years ago

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

CNS Pharmaceuticals Registration statement: Registration Filing

Jul 12, 2024, 8:00 AM EDT - 2 years ago

CNS Pharmaceuticals Registration statement: Registration Filing

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

Jul 3, 2024, 11:10 AM EDT - 2 years ago

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

CNS Pharmaceuticals Registration statement: Registration Filing

Jun 10, 2024, 8:00 AM EDT - 2 years ago

CNS Pharmaceuticals Registration statement: Registration Filing

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 20, 2024, 8:30 AM EDT - 2 years ago

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

CNS Pharmaceuticals Quarterly report: Q1 2024

May 16, 2024, 8:00 AM EDT - 2 years ago

CNS Pharmaceuticals Quarterly report: Q1 2024

CNS Pharmaceuticals Earnings release: Q1 2024

May 16, 2024, 8:00 AM EDT - 2 years ago

CNS Pharmaceuticals Earnings release: Q1 2024

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

May 16, 2024, 7:45 AM EDT - 2 years ago

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

ClarityOfPurpose2
ClarityOfPurpose2 May. 22 at 7:57 PM
$CNSP The progress made so far is that they didn’t go bankrupt or get delisted. They have enough money now to keep the lights on and pay the executive salaries and to think big thoughts for a while longer. Until the next reverse split and private placement.
0 · Reply
NetworkNewsWire
NetworkNewsWire May. 22 at 7:15 PM
Study Finds That Errors in Brain Cell Division Could Trigger Cancer $CNSP https://ibn.fm/uJ1L4 #biomed #stocks
0 · Reply
Sw1ngb0t
Sw1ngb0t May. 22 at 12:51 AM
$CNSP $VRAX weekly gap always fills... one of my new things. I really like these though
0 · Reply
30PERCENT40
30PERCENT40 May. 21 at 10:48 PM
$CNSP
0 · Reply
Sw1ngb0t
Sw1ngb0t May. 20 at 5:52 PM
$CNSP $2.40 then $40... you heard it here first
1 · Reply
Sw1ngb0t
Sw1ngb0t May. 20 at 2:51 PM
$CNSP let it come down to $2.40 then fill the boots
0 · Reply
VirtualInvestor
VirtualInvestor May. 20 at 1:49 PM
$CNSP CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company’s Recent Strategic Transformation Progress https://vimeo.com/1193965352/6cf0543a22
0 · Reply
focafoca99
focafoca99 May. 20 at 1:11 PM
$CNSP outlined its recent $22.5 million financing and strategic transformation progress during a virtual CEO Connect segment.
0 · Reply
Sw1ngb0t
Sw1ngb0t May. 20 at 12:13 PM
$CNSP I say $4 will be a good entry... let's see
0 · Reply
Sw1ngb0t
Sw1ngb0t May. 20 at 2:17 AM
$WOK (gotta watch this one...) $CNSP $CMND $ONFO $CMND
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT May. 18 at 11:01 AM
$ARTL watch out for armistice they are a self proclaimed long/short fund look what they have done to $CNSP on a 5 yr chart reversed 1/900,000 its toxic vulture finance they make $$$ when the stock goes down
1 · Reply
ClarityOfPurpose2
ClarityOfPurpose2 May. 14 at 10:58 PM
$CNSP You have to wonder whether the same people who gave them the private placement money also helped to subsequently pump the price, then sold their positions, and now are shorting the stock.
0 · Reply
NetworkNewsWire
NetworkNewsWire May. 14 at 7:55 PM
Study Suggests Testosterone Slows Glioblastoma Progression in Men $CNSP https://ibn.fm/l1qGw #biomed #stocks
0 · Reply
NetworkNewsWire
NetworkNewsWire May. 14 at 7:01 PM
MissionIRNewsBreaks – $CNSP Reports First-Quarter 2026 Results, Advances Strategic Transformation https://ibn.fm/jkNMs
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT May. 13 at 8:58 PM
$CNSP i hope you get the rip you are looking for this one is toxic though, it will go much lower just look at the history
0 · Reply
kl7777
kl7777 May. 12 at 4:45 PM
$CNSP Smaller volume today so far. But, 0 shares to short ~ 867% short borrow fee(CTB), 13 min ago
1 · Reply
Sw1ngb0t
Sw1ngb0t May. 12 at 12:19 PM
$CNSP looking primed
0 · Reply
NMWOLF
NMWOLF May. 12 at 5:16 AM
$CNSP interesting $HAO Oversold $LEDS Hot and this can fly
0 · Reply
kl7777
kl7777 May. 11 at 7:48 PM
$CNSP Short shares: 5,000 CTB(borrow fee) : 867%, 15 min ago
0 · Reply
Himan93
Himan93 May. 11 at 7:06 PM
$CNSP
0 · Reply
kl7777
kl7777 May. 8 at 5:36 PM
$CNSP Need more volume to move back to $15. A new post today on company's X account @cns_pharma, "advancing strategy w/ purpose together."
0 · Reply
Helpanyone
Helpanyone May. 7 at 7:20 PM
$CNSP lowering the bid not going to keep working !!! Going to be caught offside soon!!
0 · Reply